Biography

Dr. Aggarwal is currently a Founding Director of the Inflammation Research Center in San Diego, California. He is also currently serving on the Advisory Board of several Nutraceutical companies. Until December 31st, 2015, Dr. Aggarwal was a Ransom Horne Distinguished Professor of Experimental Therapeutics, Cancer Research, Cancer Medicine, Biochemistry and Immunology; and Chief of the Cytokine Research Section, in the Department of Experimental Therapeutics at the University of Texas M. D. Anderson Cancer Center, Houston, Texas. He also served as a member of the University of Texas Graduate School of Biomedical Sciences, Houston, and as an Adjunct Professor at Albert B. Alkek Institute of Biosciences and Technology, Texas A&M University, Houston, Texas. Dr. Aggarwal arrived in the United States as a National Scholar of the Government of India and earned his Ph. D. in Biochemistry from the University of California, Berkeley. He then joined as a Post-Doctoral Fellow in the Hormone Research Laboratory at the University of California Medical Center, San Francisco while being supported by the Rockefeller Foundation Fellowship. Thereafter, Dr. Aggarwal started his career with the then start-up Biotechnology company, Genentech Inc in South San Francisco where he worked for almost ten years and his work lead to the discovery of two cytokines, TNF-a and TNF-b, an essential component of the immune system; and identification of their receptors. In 1989, Dr. Aggarwal was recruited as a Professor of Medicine and of Clinical Immunology & Biological Therapy, Chief of the Cytokine Research section at the University of Texas M. D. Anderson Cancer Center. Since then Dr. Aggarwal has been investigating the “Role of Inflammatory Pathways Mediated through TNF, NF-kappaB, STAT3, and CXCR4 for the Prevention and Therapy of Cancer, Osteoporosis and other Chronic Diseases”. While searching for novel and safe anti-inflammatory agents, his group identified more than fifty novel compounds from mother nature including spices, dietary agents and from Traditional Medicine that interrupt these cell-signaling pathways. These agents have been tested in various animal models and some of them are in Clinical Trials. He has published over 700 publications in peer-reviewed international journals (including Science, Nature, Cancer Cell, PNAS, Journal of Experimental Medicine, Blood, Journal of Biological Chemistry, Cancer Research, Journal of Immunology), invited reviews and book chapters. He has also been a co-organizer of two International Conferences on “Translational Cancer Research” since 2004 and “Nutraceuticals and Chronic Diseases” since 2012